Enjoy complimentary customisation on priority with our Enterprise License!
Tuberculosis is a disease caused by a bacterium called Mycobacterium Tuberculosis. This bacterium is present in the air and spreads from one person to another. It usually affects the lungs and can also target other body parts, including the spine, brain, and kidneys. According to the Centers for Disease Control and Prevention (CDC), 10.4 million people worldwide became sick with TB in 2016. Furthermore, 1.7 million TB-related deaths were reported worldwide. As per NIH, the incidence rate worldwide was 122 cases per 100,000 population in 2012. The prevalence of tuberculosis cases were the highest from the Western Pacific, Africa, Eastern Mediterranean region, Europe, and the Americas. As a result, this has encouraged market vendors to form collaborations with various non-profit organizations, such as The TB Alliance and Aeras, for the treatment of tuberculosis. Drug developing companies provide funding and help to initiate the research and development process by providing a dedicated R&D team. As a result, with the increasing incidences of tuberculosis, the drug development for tuberculosis will be promoted significantly during the predicted period.
According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for tuberculosis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of tuberculosis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
The oral route of administration (ROA) involves the application of the drug directly through the mouth, which will have a more direct effect on the target cells.
According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for tuberculosis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.